1278 - Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment with Baseline Viral Loads ≥ 100,000 copies/mL in the US

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

PB

Paul Benson, DO, AAHIVS

Be Well Medical Center
Berkley, Michigan, United States
CD

Cindy Donovan, PharmD

ViiV Healthcare
Research Triangle Park, North Carolina, United States
GH

Gavin Harper, BA

Adelphi Real World
Bollington, England, United Kingdom
DM

Deanna Merrill, PharmD, MBA, AAHIVP

Medical Affairs Scientific Director, Research
ViiV Healthcare
Research Triangle Park, North Carolina, United States
KM

Katie L. Mycock, MChem

Associate Manager, Observational Research
Adelphi Real World
Bollington, England, United Kingdom
Alan Oglesby, MPH

Sr. Director
ViiV Healthcare
Research Triangle Park, North Carolina, United States
Jimena Patarroyo, PharmD, AAHIVP

Senior Medical Science Liaison
ViiV Healthcare
Research Triangle Park, North Carolina, United States

Aimee Metzner, PharmD, AAHIVP

US Health Outcomes Director
ViiV Healthcare
Durham, North Carolina, United States